{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:17:44Z","timestamp":1780366664871,"version":"3.54.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T00:00:00Z","timestamp":1443139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00280-015-2871-z","type":"journal-article","created":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T07:22:58Z","timestamp":1443165778000},"page":"977-987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition"],"prefix":"10.1007","volume":"76","author":[{"given":"Linna","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Scorsone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Woodfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Zage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,25]]},"reference":[{"key":"2871_CR1","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.1998.16.3.953","volume":"16","author":"R Ladenstein","year":"2009","unstructured":"Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R et al (2009) Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953\u2013965","journal-title":"J Clin Oncol"},{"key":"2871_CR2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","volume":"27","author":"KK Matthay","year":"2009","unstructured":"Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D et al (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children\u2019s Oncology Group study. J Clin Oncol 27:1007\u20131013","journal-title":"J Clin Oncol"},{"key":"2871_CR3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/pbc.21713","volume":"51","author":"PE Zage","year":"2008","unstructured":"Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y et al (2008) Outcomes of the POG 9340\/9341\/9342 trials for children with high-risk neuroblastoma: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer 51:747\u2013753","journal-title":"Pediatr Blood Cancer"},{"key":"2871_CR4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00043426-200404000-00003","volume":"26","author":"L Lau","year":"2004","unstructured":"Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D (2004) Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol 26:227\u2013232","journal-title":"J Pediatr Hematol Oncol"},{"key":"2871_CR5","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1200\/JCO.2010.34.3392","volume":"29","author":"WB London","year":"2011","unstructured":"London WB, Castel V, Monclair T, Ambros PF, Pearson ADJ, Cohn SL et al (2011) Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol 29:3286\u20133292","journal-title":"J Clin Oncol"},{"key":"2871_CR6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1172\/JCI116684","volume":"92","author":"T Matsui","year":"1993","unstructured":"Matsui T, Sano K, Tsukamoto T, Ito M, Takaishi T, Nakata H et al (1993) Human neuroblastoma cells express alpha and beta platelet-derived growth factor receptors coupling with neurotrophic and chemotactic signaling. J Clin Invest 92:1153\u20131160","journal-title":"J Clin Invest"},{"key":"2871_CR7","first-page":"3465","volume":"84","author":"PS Cohen","year":"1994","unstructured":"Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC (1994) Expression of stem cell factor and c-kit in human neuroblastoma. The Children\u2019s Cancer Group. Blood 84:3465\u20133472","journal-title":"The Children\u2019s Cancer Group. Blood"},{"key":"2871_CR8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/jnr.490400602","volume":"40","author":"T Janet","year":"1995","unstructured":"Janet T, Ludecke G, Otten U, Unsicker K (1995) Heterogeneity of human neuroblastoma cell lines in their proliferative responses to basic FGF, NGF, and EGF: correlation with expression of growth factors and growth factor receptors. J Neurosci Res 40:707\u2013715","journal-title":"J Neurosci Res"},{"key":"2871_CR9","first-page":"1900","volume":"6","author":"A Eggert","year":"2000","unstructured":"Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP (2000) High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6:1900\u20131908","journal-title":"Clin Cancer Res"},{"key":"2871_CR10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/(SICI)1096-911X(200006)34:6<386::AID-MPO2>3.0.CO;2-3","volume":"34","author":"I Langer","year":"2000","unstructured":"Langer I, Vertongen P, Perret J, Fontaine J, Atassi G, Robberecht P (2000) Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med Pediatr Oncol 34:386\u2013393","journal-title":"Med Pediatr Oncol"},{"key":"2871_CR11","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1158\/0008-5472.CAN-04-1014","volume":"64","author":"M Hecht","year":"2004","unstructured":"Hecht M, Papoutsi M, Tran HD, Wilting J, Schweigerer L (2004) Hepatocyte growth factor\/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Res 64:6109\u20136118","journal-title":"Cancer Res"},{"key":"2871_CR12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jcb.240380203","volume":"38","author":"MB Meyers","year":"1998","unstructured":"Meyers MB, Shen WP, Spengler BA, Ciccarone V, O\u2019Brien JP, Donner DB et al (1998) Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem 38:87\u201397","journal-title":"J Cell Biochem"},{"key":"2871_CR13","doi-asserted-by":"crossref","first-page":"9868","DOI":"10.1158\/0008-5472.CAN-04-2426","volume":"65","author":"R Ho","year":"2005","unstructured":"Ho R, Minturn JE, Hishiki T, Zhao H, Wang Q, Cnaan A et al (2005) Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 65:9868\u20139875","journal-title":"Cancer Res"},{"key":"2871_CR14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0959-8049(98)00387-6","volume":"35","author":"B Meister","year":"1999","unstructured":"Meister B, Grunebach F, Bautz F, Brugger W, Fink FM, Kanz L, Mohle R (1999) Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma. Eur J Cancer 35:445\u2013449","journal-title":"Eur J Cancer"},{"key":"2871_CR15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/jpsu.2002.31614","volume":"37","author":"M Fakhari","year":"2002","unstructured":"Fakhari M, Pullirsch D, Paya K, Abraham D, Hofbauer R, Aharinejad S (2002) Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. J Pediatr Surg 37:582\u2013587","journal-title":"J Pediatr Surg"},{"key":"2871_CR16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/1471-2407-9-411","volume":"9","author":"HE Crosswell","year":"2009","unstructured":"Crosswell HE, Dasgupta A, Alvarado CS, Watt T, Christensen JG, De P et al (2009) PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer 9:411","journal-title":"BMC Cancer"},{"key":"2871_CR17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-642-54490-3_12","volume":"201","author":"C Gr\u00fcllich","year":"2014","unstructured":"Gr\u00fcllich C (2014) Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Recent Results Cancer Res 201:207\u2013214","journal-title":"Recent Results Cancer Res"},{"key":"2871_CR18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2217\/fon.13.128","volume":"9","author":"D Viola","year":"2013","unstructured":"Viola D, Cappagli V, Elisei R (2013) Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncol 9:1083\u20131092","journal-title":"Future Oncol"},{"key":"2871_CR19","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P et al (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10:2298\u20132308","journal-title":"Mol Cancer Ther"},{"key":"2871_CR20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","volume":"2","author":"B Sennino","year":"2012","unstructured":"Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V et al (2012) Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2:270\u2013287","journal-title":"Cancer Discov"},{"key":"2871_CR21","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","volume":"29","author":"R Kurzrock","year":"2011","unstructured":"Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R et al (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660\u20132666","journal-title":"J Clin Oncol"},{"key":"2871_CR22","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/jco.2011.29.15_suppl.3010","volume":"29","author":"MS Gordon","year":"2011","unstructured":"Gordon MS, Vogelzang NJ, Schoffski P, Daud A, Spira AI, O\u2019Keeffe BA et al (2011) Cabozantinib (XL184) has activity in both soft tissue and bone: results of a phase II randomized discontinuation trial in patients with advanced solid tumors. J Clin Oncol 29:3010","journal-title":"J Clin Oncol"},{"key":"2871_CR23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2159-8290.CD-13-0035","volume":"3","author":"A Drilon","year":"2013","unstructured":"Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P et al (2013) Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3:630\u2013635","journal-title":"Cancer Discov"},{"key":"2871_CR24","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.2013.54.5954","volume":"32","author":"MR Smith","year":"2014","unstructured":"Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M et al (2014) Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol 32:3391\u20133399","journal-title":"J Clin Oncol"},{"key":"2871_CR25","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/annonc\/mdu184","volume":"25","author":"TK Choueiri","year":"2014","unstructured":"Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J et al (2014) A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 25:1603\u20131608","journal-title":"Ann Oncol"},{"key":"2871_CR26","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, M\u00fcller SP, Sch\u00f6ffski P, Brose MS, Shah MH et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639\u20133646","journal-title":"J Clin Oncol"},{"key":"2871_CR27","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1002\/cncr.25017","volume":"116","author":"PE Zage","year":"2010","unstructured":"Zage PE, Zeng L, Palla S, Fang W, Nilsson MB, Heymach JV et al (2010) A novel therapeutic combination for neuroblastoma: the VEGFR\/EGFR\/RET inhibitor vandetanib with 13-cis-retinoic acid. Cancer 116:2465\u20132475","journal-title":"Cancer"},{"key":"2871_CR28","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/jclinpath-2012-201375","volume":"66","author":"B Yan","year":"2013","unstructured":"Yan B, Lim M, Zhou L, Kuick CH, Leong MY, Yong KJ et al (2013) Identification of MET genomic amplification, protein expression, and alternative splice isoforms in neuroblastomas. J Clin Pathol 66:985\u2013991","journal-title":"J Clin Pathol"},{"key":"2871_CR29","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10637-014-0107-4","volume":"32","author":"K Scorsone","year":"2014","unstructured":"Scorsone K, Zhang L, Woodfield SE, Hicks J, Zage PE (2014) The novel kinase inhibitor EMD1214063 is effective against neuroblastoma. Invest New Drugs 32:815\u2013824","journal-title":"Invest New Drugs"},{"key":"2871_CR30","first-page":"2643","volume":"33","author":"JL Biedler","year":"1973","unstructured":"Biedler JL, Helson L, Spengler BA (1973) Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 33:2643\u20132652","journal-title":"Cancer Res"},{"key":"2871_CR31","first-page":"4678","volume":"41","author":"GM Brodeur","year":"1981","unstructured":"Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA (1981) Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41:4678\u20134686","journal-title":"Cancer Res"},{"key":"2871_CR32","first-page":"291","volume":"271","author":"CP Reynolds","year":"1988","unstructured":"Reynolds CP, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ et al (1988) Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res 271:291\u2013306","journal-title":"Prog Clin Biol Res"},{"key":"2871_CR33","first-page":"3094","volume":"36","author":"HR Schlesinger","year":"1976","unstructured":"Schlesinger HR, Gerson JM, Moorhead PS, Maguire H, Hummeler K (1976) Establishment and characterization of human neuroblastoma cell line. Cancer Res 36:3094\u20133100","journal-title":"Cancer Res"},{"key":"2871_CR34","first-page":"5396","volume":"58","author":"N Keshelava","year":"1998","unstructured":"Keshelava N, Seeger RC, Groshen S, Reynolds CP (1998) Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58:5396\u20135405","journal-title":"Cancer Res"},{"key":"2871_CR35","first-page":"2110","volume":"30","author":"JJ Tumilowicz","year":"1970","unstructured":"Tumilowicz JJ, Nichols WW, Cholon JJ, Greene AE (1970) Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 30:2110\u20132118","journal-title":"Cancer Res"},{"key":"2871_CR36","first-page":"219","volume":"49","author":"V Ciccarone","year":"1989","unstructured":"Ciccarone V, Spengler BA, Meyers MB, Biedler JL, Ross RA (1989) Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res 49:219\u2013225","journal-title":"Cancer Res"},{"key":"2871_CR37","first-page":"51","volume":"73","author":"T Sugimoto","year":"1984","unstructured":"Sugimoto T, Tatsumi E, Kemshed JT, Helson L, Green AA, Minowada J (1984) Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia\u2013lymphoma cell lines by a panel of 38 monoclonal antibodies. J Natl Cancer Inst 73:51\u201357","journal-title":"J Natl Cancer Inst"},{"key":"2871_CR38","first-page":"39","volume":"3","author":"L Helson","year":"1985","unstructured":"Helson L, Helson C (1985) Human neuroblastoma cells and 13-cis-retinoic acid. J Neurooncol 3:39\u201341","journal-title":"J Neurooncol"},{"key":"2871_CR39","first-page":"5444","volume":"44","author":"F Gilbert","year":"1984","unstructured":"Gilbert F, Feder M, Balaban G, Brangman D, Lurie DK, Podolsky R, Rinaldt V, Vinikoor N, Weisband J (1984) Human neuroblastoma and abnormalities of chromosomes 1 and 17. Cancer Res 44:5444\u20135449","journal-title":"Cancer Res"},{"key":"2871_CR40","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1200\/JCO.2005.02.097","volume":"23","author":"VM Santana","year":"2005","unstructured":"Santana VM, Furman WL, Billups CA, Hoffer F, Davidoff AM, Houghton PJ et al (2005) Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 23:4039\u20134047","journal-title":"J Clin Oncol"},{"key":"2871_CR41","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1200\/JCO.2006.06.1572","volume":"24","author":"H Rubie","year":"2006","unstructured":"Rubie H, Chisholm J, Defachelles AS, Morland B, Munzer C, Valteau-Couanet D et al (2006) Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Societe Francaise des Cancers de l\u2019Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. J Clin Oncol 24:5259\u20135264","journal-title":"J Clin Oncol"},{"key":"2871_CR42","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1471::AID-CNCR1>3.0.CO;2-6","volume":"83","author":"WH Miller","year":"1998","unstructured":"Miller WH (1998) The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 83:1471\u20131482","journal-title":"Cancer"},{"key":"2871_CR43","first-page":"589","volume":"68","author":"N Sidell","year":"1982","unstructured":"Sidell N (1982) Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst 68:589\u2013596","journal-title":"J Natl Cancer Inst"},{"key":"2871_CR44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0014-4827(83)90184-2","volume":"148","author":"N Sidell","year":"1983","unstructured":"Sidell N, Altman A, Haussler MR, Seeger RC (1983) Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res 148:21\u201330","journal-title":"Exp Cell Res"},{"key":"2871_CR45","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/313404a0","volume":"313","author":"CJ Thiele","year":"1985","unstructured":"Thiele CJ, Reynolds CP, Israel MA (1985) Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313:404\u2013406","journal-title":"Nature"},{"key":"2871_CR46","first-page":"2158","volume":"58","author":"T Hishiki","year":"1998","unstructured":"Hishiki T, Nimura Y, Isogai E, Kondo K, Ichimiya S, Nakamura Y et al (1998) Glial cell line-derived neurotrophic factor\/neurturin-induced differentiation and its enhancement by retinoic acid in primary human neuroblastomas expressing c-Ret, GFR alpha-1, and GFR alpha-2. Cancer Res 58:2158\u20132165","journal-title":"Cancer Res"},{"key":"2871_CR47","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/1535-7163.MCT-06-0587","volume":"6","author":"O Oppenheimer","year":"2007","unstructured":"Oppenheimer O, Cheung N-K, Gerald WL (2007) The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther 6:1300\u20131309","journal-title":"Mol Cancer Ther"},{"key":"2871_CR48","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1006\/excr.1995.1067","volume":"217","author":"G Bunone","year":"1995","unstructured":"Bunone G, Borrello MG, Picetti R, Bongarzone I, Peverali FA, de Franciscis V et al (1995) Induction of RET proto-oncogene expression in neuroblastoma cells precedes neuronal differentiation and is not mediated by protein synthesis. Exp Cell Res 217:92\u201399","journal-title":"Exp Cell Res"},{"key":"2871_CR49","first-page":"1387","volume":"6","author":"A D\u2019Aleesio","year":"1995","unstructured":"D\u2019Aleesio A, De Vita G, Cali G, Nitsch L, Fusco A, Vecchio G et al (1995) Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells. Cell Growth Differ 6:1387\u20131394","journal-title":"Cell Growth Differ"},{"key":"2871_CR50","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1046\/j.1471-4159.2000.0750991.x","volume":"75","author":"M Encinas","year":"2000","unstructured":"Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V et al (2000) Sequential treatment of SH-SY5Y Cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem 75:991\u20131003","journal-title":"J Neurochem"},{"key":"2871_CR51","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/1096-911X(20010101)36:1<122::AID-MPO1029>3.0.CO;2-R","volume":"36","author":"N Takada","year":"2001","unstructured":"Takada N, Isogai E, Kawamoto Nakanishi H, Todo S, Nakagawara A (2001) Retinoic acid-induced apoptosis of the CHP134 neuroblastoma cell line is associated with nuclear accumulation of p53 and is rescued by the GDNF\/Ret signal. Med Pediatr Oncol 36:122\u2013126","journal-title":"Med Pediatr Oncol"},{"key":"2871_CR52","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/pbc.22352","volume":"54","author":"H Carol","year":"2010","unstructured":"Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Watkins A, Smith MA, Lock RB (2010) Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer 54:707\u2013715","journal-title":"Pediatr Blood Cancer"},{"key":"2871_CR53","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/pbc.24368","volume":"60","author":"ST Keir","year":"2013","unstructured":"Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA (2013) Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer 60:783\u2013790","journal-title":"Pediatr Blood Cancer"},{"key":"2871_CR54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1651-2227.2004.tb03048.x","volume":"445","author":"A Donfrancesco","year":"2004","unstructured":"Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano GM, De Sio L, Cozza R, Fifani P, Deb G, De Laurentis C, Inserra A, Dominici C (2004) Ifosfamide\/carboplatin\/etoposide (ICE) as front-line, topotecan\/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Pediatr 445:6\u201311","journal-title":"Acta Pediatr"},{"key":"2871_CR55","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2009.27.5016","volume":"28","author":"WB London","year":"2010","unstructured":"London WB, Frantz CN, Campbell LA, Seeger RC, Brumback BA, Cohn SL, Matthay KK, Castleberry RP, Diller L (2010) Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a children\u2019s oncology group study. J Clin Oncol 28:3808\u20133815","journal-title":"J Clin Oncol"},{"key":"2871_CR56","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1200\/JCO.2006.06.7272","volume":"24","author":"BH Kushner","year":"2006","unstructured":"Kushner BH, Kramer K, Modak S, Cheung N-KV (2006) Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 24:5271\u20135276","journal-title":"J Clin Oncol"},{"key":"2871_CR57","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.2010.31.7107","volume":"29","author":"R Bagatell","year":"2011","unstructured":"Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, Kretschmar C, Cohn SL (2011) Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a children\u2019s oncology group study. J Clin Oncol 29:208\u2013213","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2871-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2871-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2871-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T10:34:21Z","timestamp":1718102061000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2871-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,25]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["2871"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2871-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,25]]}}}